Evidence map›Paper›PMID 31797405›Full record

ReviewJournal of neuroscience research2020

PPARα serves as a new receptor of aspirin for neuroprotection.

Dhruv Patel, Avik Roy, Kalipada Pahan

Abstract readReview
In one paragraph

Review in Journal of neuroscience research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. PPARɑ Ligand Caudatin Improves Cognitive Functions and Mitigates Alzheimer's Disease Defects By Inducing Autophagy in Mice Models.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Dhruv PatelDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.ORCID 0000-0002-5438-1051
Avik RoyDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.ORCID 0000-0003-0523-8504
Kalipada PahanDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.ORCID 0000-0001-6048-9598
Rush University Medical Center · US

Funding

Characterizing novel hippocampal drugs for Alzheimer's diseaseR01AG050431 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI PAHAN, KALIPADA · 2016 to 2020
$2.1M
Aspirin, PPAR and EAEI01BX002174 · VA · JESSE BROWN VA MEDICAL CENTER · PI PAHAN, KALIPADA · 2013 to 2016
–
BLR&D Research Career Scientist ApplicationIK6BX004982 · VA · JESSE BROWN VA MEDICAL CENTER · PI KALIPADA PAHAN · 2020 to 2026
–
BLRD VA I01 BX002174BLRD VA I01 BX005002BLRD VA IK6 BX004982NIA NIH HHS R01 AG050431NIH HHS AG050431Veteran Affairs I01BX002174Zenith Fellows Award ZEN-17-438829
6 · The paper itself

Abstract

Acetyl salicylic acid, commonly known as aspirin, has been being widely used as an anti-inflammatory drug for almost 100 years. However, there was no receptor known for this popular drug. Recently, we have established that peroxisome proliferator-activated receptor alpha (PPARα) acts as a novel receptor of aspirin. Activation of PPARα by aspirin stimulated a series of downstream signaling pathways that could potentially ameliorate different Alzheimer's disease (AD)-related pathologies. In this mini-review, we have discussed how aspirin-PPARα interaction plays a pivotal role in the amelioration of AD pathology via the stimulation of neurotrophic factors, upregulation of plasticity-associated genes, and removal of plaque burden in hippocampal neurons.

Indexed as

Alzheimer DiseaseAnimalsAspirinBrainHumansNeuronal PlasticityNeuronsNeuroprotective AgentsPlaque, AmyloidPPAR alphaSignal TransductionAspirinNeuroprotective AgentsPPAR alphaAlzheimer's diseaseBDNFcalcium influxhippocampal plasticityPPARαspine density

Identifiers

PMID31797405
PMCPMC7015783
OpenAlexW2993477809

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.